{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-130675","form_type":"8-K","ticker":"MRK","cik":"0000310158","company_name":"Merck & Co., Inc.","filed_at":"2021-10-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:15.034407+00:00","generated_at":"2026-06-28T17:00:55.211907+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Merck Q3 sales $13.2B (+20% YoY); raises FY2021 guidance; to acquire Acceleron for $11.5B","bullets":["Q3 GAAP EPS $1.80, Non-GAAP EPS $1.75; sales $13.2B (+20% YoY, +19% ex-FX).","Keytruda sales $4.5B (+22%); Gardasil $2.0B (+68%); Animal Health $1.4B (+16%).","Raises FY2021 revenue guidance to $47.4B–$47.9B; Non-GAAP EPS to $5.65–$5.70.","Agreement to acquire Acceleron Pharma for $180/share (~$11.5B); expected close Q4 2021.","Submitted EUA for molnupiravir (oral COVID-19 treatment) based on positive Phase 3 data."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-130675","json":"https://secwatch.observer/filing/0001104659-21-130675.json","markdown":"https://secwatch.observer/filing/0001104659-21-130675.md","text":"https://secwatch.observer/filing/0001104659-21-130675.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/310158/000110465921130675/0001104659-21-130675-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/310158/000110465921130675/tm2131077d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T17:00:55.211907+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}